U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07062354) titled 'Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer' on July 02.
Brief Summary: This research study is for people who have head and neck cancer that has come back or spread to other places in the body.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Head &Amp; Neck Cancer
Head &Amp; Neck Squamous Cell Carcinoma
Intervention:
DRUG: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
Carboplatin + Paclitaxel + Amivantamab hyaluronidase
Recruitment Status: NOT_YET_RECRUITING
Sponsor: SWOG Cancer Research Net...